PepiX Platform Programs
Various
DiscoveryActive
Key Facts
About XtalPi
Founded in 2014 by MIT physicists, XtalPi has evolved from a pioneer in crystal structure prediction (CSP) into a comprehensive AI and automation platform for drug discovery. The company leverages a proprietary 'Hybrid AI + QM Discovery Engine' that combines quantum mechanics, machine learning, and robotic labs to design, predict, and synthesize novel drug candidates with high efficiency. With over 80 partners in pharma and biotech, a team of 1000+ employees, and a proven track record including contributions to Paxlovid's development, XtalPi is positioned as a key technology enabler in the rapidly growing AI-driven drug discovery sector.
View full company profileOther Various Drugs
| Drug | Company | Phase |
|---|---|---|
| New Generic Approvals | China SXT Pharmaceuticals | Application Submitted / BE Stage |
| New Dosage Form Development | Universe Pharmaceuticals | Development |
| New TCM Formula Registration | Universe Pharmaceuticals | Development |
| CBD/THC Oil Formulation | Avecho Biotechnology | Preclinical |
| Bag APIs | ChemWerth | Approved |
| Oral APIs | ChemWerth | Approved |
| Companion Diagnostics Development | Kiffik Biomedical | Pre-clinical |
| Portfolio of Complex Generics & 505(b)(2) Products | Alvogen | Approved/Commercial |
| Portfolio of 40+ products | Praxgen Pharmaceuticals | Development |
| Drug Repositioning Service | Biovista | Service |
| Custom Control Development | Anchor Molecular | Development/Commercial |
| Portfolio from Steriscience Partnership | Armas Pharmaceuticals | ANDA Development/Filing |